Hemostemix Inc V.HEM

Alternate Symbol(s): HMTXF

Healthcare Biotechnology

Hemostemix Inc. is a Canada-based clinical-stage biotechnology company. The Company’s principal business is to develop, manufacture and commercialize blood-derived stem cell therapies to treat various diseases. It is an autologous stem cell therapeutics company that holds 91 patents on the derivation of three stem cell lineages from the patient’s blood, including angiogenic cell precursors (ACP-01), neuronal cell precursors, and cardiomyocyte cell precursors. ACP-01 is a lead clinical-stage candidate, like NCP-01 and CCP-01, is generated from the patient’s blood. The Company is engaged in providing treatment for ischemia, such as ischemic cardiomyopathy, angina, peripheral arterial disease including critical limb ischemia. The Company’s proprietary technology is a personalized regenerative therapy that is administered to a patient within seven days of the initial blood draw. Its subsidiaries include Kwalata Trading Limited, Hemostemix Ltd., and PreCerv Inc.

TSXV:HEM - Post by User

Hemostemix Inc

Bullboard Posts

Comment by dt_coreon Apr 06, 2011 12:59pm

213 Views

Post# 18393996

RE: RE: Shorts are covered

"I still suspect it was Wellington and/or Canaccord who shorted"

You really think so? Who would give them the borrow?

As mentioned prior, I think the cover occured on the 16th/17th when we had that sudden run-up ahead of the quarter. Interesting that no new shorts came on after the quarter was announced (positive).

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute